Theravance Biopharma, Inc. Equity Method Investments
Theravance Biopharma, Inc. (TBPH) had Equity Method Investments of $148.25 million as of 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments
us-gaap:EquityMethodInvestments · last filed 2022-08-08
- 2022-06-30: Equity Method Investments $148.25M.
- 2022-03-31: Equity Method Investments $94.11M.
- 2021-12-31: Equity Method Investments $67.54M.
- 2021-09-30: Equity Method Investments $45.09M.
| Period end | Equity Method Investments |
|---|---|
| 2022-06-30 | $148.25M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $94.11M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $67.54M 10-Q · filed 2022-08-08 |
| 2021-09-30 | $45.09M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $35.82M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $19.44M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $12.75M 10-K · filed 2022-02-28 |
| 2020-10-31 | $12.80M 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |